SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mangalam Drugs and Organics gains on commissioning new intermediate manufacturing facility at Gujarat

21 Jun 2021 Evaluate

Mangalam Drugs & Organics is currently trading at Rs. 148.00, up by 1.05 points or 0.71% from its previous closing of Rs. 146.95 on the BSE.

The scrip opened at Rs. 146.00 and has touched a high and low of Rs. 151.90 and Rs. 143.20 respectively. So far 19959 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 175.30 on 18-Nov-2020 and a 52 week low of Rs. 60.50 on 17-Jul-2020.

Last one week high and low of the scrip stood at Rs. 156.50 and Rs. 130.05 respectively. The current market cap of the company is Rs. 229.43 crore.

The promoters holding in the company stood at 50.53%, while Institutions and Non-Institutions held 0.01% and 49.46% respectively.

Mangalam Drugs and Organics is commissioning new intermediate manufacturing facility at unit 1 located in Vapi, Gujarat. This intermediate is an import substitute and an important raw material, which the Company was importing from China. This will enable to reduce reliability on Chinese imports for this product and help to maintain uninterrupted supply chain to a great extent.

This being a multi-product manufacturing facility, it will also support production of a few more intermediates that are presently being imported from China, thus making self-sufficient to a great extent. 

Mangalam Drugs and Organics is an India-based company engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The Company’s segments include bulk drugs, and chemicals and others. 

Mangalam Drugs&Org. Share Price

29.75 0.02 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×